James Jiunta
Internal Medicine · Kingston, PANPI 1184618563
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 239 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $992 and has fallen 78.4% since, to $215 in 2023.
Across 239 payments — averaging $14.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$710
- AstraZeneca$526
- Amgen$379
- AbbVie$306
- Johnson & Johnson$265
- Teva Pharmaceuticals USA, Inc.$209
- plus $969 from 19 others
What the payments were for
- Food & beverage$3,351100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 51 | $710 |
| AstraZeneca | 40 | $526 |
| Amgen | 27 | $379 |
| AbbVie(2 entities) | 20 | $306 |
| Johnson & Johnson | 22 | $265 |
| Teva Pharmaceuticals USA, Inc. | 15 | $209 |
| Lilly USA, LLC | 8 | $122 |
| Amarin Pharma, Inc. | 7 | $106 |
| Novartis | 6 | $102 |
| Boehringer Ingelheim | 7 | $101 |
| Bayer | 5 | $68 |
| Pfizer | 4 | $65 |
| GSK | 4 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $56 |
| E.r. Squibb & Sons, L.L.C. | 4 | $51 |
| Esperion Therapeutics, Inc. | 2 | $40 |
| Exact Sciences | 2 | $36 |
| Biodelivery Sciences International, Inc. | 2 | $31 |
| Abbott | 2 | $31 |
| Adamas Pharmaceuticals, Inc. | 2 | $27 |
| IBSA Pharma Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$3,365 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 13 | $294 |
| Allopurinol | 19 | $191 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Kingston
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Christopher StillDanville$442K
- Jeffrey FreidLower Gwynedd$425K
- Cheryl PegusSpring House$370K
- Eyob FeyssaPhiladelphia$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.